Pharmacokinetic Properties of Nevirapine Extended Release Tablets When Administered Orally in Healthy Male Volunteers
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to determine the pharmacokinetic properties of 200 mg nevirapine (NVP) administered as
4 x 50 mg extended release (XR) tablets in a single dose and to establish the bioequivalence
of this formulation compared to 200 mg NVP administered as 2 x 100 mg XR tablets in a single
dose